1-3 of 3
Michael van der Veer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Human CD38 Monoclonal Antibody Daratumumab Improves the Anti-Myeloma Effect of Lenalidomide with Dexamethasone in Vitro

Michel de Weers, PhD, Michael van der Veer, Berris van Kessel, Joost M Bakker, PhD, Shulamiet Wittebol, MD, Paul WHI Parren, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD
Journal: Blood
Blood (2011) 118 (21): 5106.
https://doi.org/10.1182/blood.V118.21.5106.5106
Published: 2011
Journal Articles

In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma

Richard W Groen, Michael van der Veer, Frans M Hofhuis, Berris van Kessel, Michel de Weers, PhD, Paul W.H.I. Parren, PhD, Henk M Lokhorst, MD, PhD, Tuna Mutis, MD, PhD, Anton Martens, PhD
Journal: Blood
Blood (2010) 116 (21): 3058.
https://doi.org/10.1182/blood.V116.21.3058.3058
Published: 2010
Journal Articles

Lenalidomide Is Highly Effective in Patients with Relapsed Multiple Myeloma Following Allogeneic Stem Cell Transplantation and Increases the Frequency of CD4 + FOXP3 + T Cells.

Monique C. Minnema, MD, Michael van der Veer, Tineke Aarts, Maarten Emmelot, Tuna Mutis, PhD, Henk M. Lokhorst, MD
Journal: Blood
Blood (2007) 110 (11): 2722.
https://doi.org/10.1182/blood.V110.11.2722.2722
Published: 2007